Bone Density & Fracture Risk
Low Testosterone, BMD, and the TRAVERSE Fracture Paradox
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Testosterone is not FDA-approved to prevent fractures or treat osteoporosis; bisphosphonates/anti-resorptives are the approved skeletal therapies
Reference only. Not medical advice.
What can go wrong
Relying on testosterone for fracture prevention is unsupported and, per TRAVERSE, possibly counterproductive. Men with osteoporosis need bone-directed evaluation and approved anti-resorptive/anabolic agents; testosterone, if used, addresses hypogonadism, not fracture risk per se. Older men on testosterone also face fall-relevant and erythrocytosis risks.
This is something to take to a clinician. The Atlas can tell you what is known about bone density & fracture risk in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Low testosterone in men is a recognized contributor to bone loss (testosterone supports bone partly via aromatization to estradiol, the dominant regulator of male skeletal maintenance), and frank hypogonadism is a secondary cause of osteoporosis. Treating hypogonadal older men with testosterone increases bone mineral density: the T-Trials Bone substudy (Snyder et al., JAMA Internal Medicine 2017) showed significant gains in volumetric BMD and estimated bone strength, especially in trabecular spine. Yet, paradoxically, the larger TRAVERSE trial's fracture analysis (Snyder et al., NEJM 2024) found MORE clinical fractures in the testosterone group, an unresolved contradiction that warns against assuming density gains equal fracture protection.
Testosterone builds bone density, yet the biggest trial counted more fractures.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
In men, much of testosterone's skeletal effect is indirect, via aromatization to estradiol, which restrains bone resorption; testosterone also acts directly on osteoblasts. Replacing testosterone in deficient men raises BMD measurably over a year. But BMD is a surrogate; fracture is the outcome, and the two diverged in TRAVERSE.
The density-fracture disconnect
The standard story, low T weakens bone, testosterone strengthens it, predicts fewer fractures on therapy. TRAVERSE inverted that prediction: despite testosterone's known density benefit and the T-Trials' positive BMD data, the testosterone group sustained MORE clinical fractures than placebo. Possible explanations under investigation include increased physical activity/fall exposure, chance, or unmeasured effects on bone quality, but the bottom line is that BMD gains cannot be assumed to translate into fracture prevention. Testosterone is not an approved anti-fracture therapy.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- DXA / bone density where osteoporosis suspected
- Estradiol (key for male bone)
- Fall-risk assessment in older men
- Appropriate referral for approved osteoporosis therapy
What people get wrong
Often saidTestosterone prevents fractures in aging men
ActuallyIt raises BMD (a surrogate), but TRAVERSE found MORE fractures on testosterone. It is not an approved or proven anti-fracture therapy.
Often saidHigher density automatically means fewer breaks
ActuallyThe T-Trials showed density gains; TRAVERSE showed more fractures. Density and fracture outcomes diverged.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- Why did TRAVERSE fractures rise despite higher BMD, behavior, bone quality, or chance?
- Does the estradiol fraction (not testosterone itself) carry most of the skeletal benefit, and what does aromatase-inhibitor 'optimization' do to bone?
At a glance
- Estradiol's role
- Dominant regulator of male bone (via aromatization)
- Low T effect
- Contributes to bone loss; secondary osteoporosis
- BMD trial
- T-Trials Bone (Snyder, JAMA Intern Med 2017)
- BMD result
- Significant vBMD and bone-strength gains
- Fracture trial
- TRAVERSE fracture analysis (NEJM 2024)
- Fracture result
- MORE fractures on testosterone (paradox)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Bone Density & Fracture Risk. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
T-Trials Bone, Snyder et al., JAMA Internal Medicine2017
One year of testosterone in men 65+ significantly increased volumetric BMD and estimated bone strength, most in trabecular spine
TRAVERSE fracture analysis, Snyder et al., NEJM2024
Testosterone group had MORE clinical fractures than placebo despite the expected density benefit, an unexplained paradox
EMAS / observational bone data2010s
Low testosterone (and low estradiol) associated with lower BMD and higher fracture risk in aging men, supporting a contributory role